| Literature DB >> 25538631 |
Celia J A Morgan1, Chris M Dodds2, Hannah Furby3, Fiona Pepper4, Johnson Fam5, Tom P Freeman6, Emer Hughes5, Christian Doeller7, John King6, Oliver Howes5, James M Stone8.
Abstract
Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is rising in popularity as a drug of abuse. Preliminary evidence suggests that chronic, heavy ketamine use may have profound effects on spatial memory but the mechanism of these deficits is as yet unclear. This study aimed to examine the neural mechanism by which heavy ketamine use impairs spatial memory processing. In a sample of 11 frequent ketamine users and 15 poly-drug controls, matched for IQ, age, years in education. We used fMRI utilizing an ROI approach to examine the neural activity of three regions known to support successful navigation; the hippocampus, parahippocampal gyrus, and the caudate nucleus during a virtual reality task of spatial memory. Frequent ketamine users displayed spatial memory deficits, accompanied by and related to, reduced activation in both the right hippocampus and left parahippocampal gyrus during navigation from memory, and in the left caudate during memory updating, compared to controls. Ketamine users also exhibited schizotypal and dissociative symptoms that were related to hippocampal activation. Impairments in spatial memory observed in ketamine users are related to changes in medial temporal lobe activation. Disrupted medial temporal lobe function may be a consequence of chronic ketamine abuse and may relate to schizophrenia-like symptomatology observed in ketamine users.Entities:
Keywords: NMDA receptor; drug abuse; hippocampus; ketamine; memory; spatial memory
Year: 2014 PMID: 25538631 PMCID: PMC4255515 DOI: 10.3389/fpsyt.2014.00149
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1(A) Trial structure in experimental trials. Participants are presented with an object cue and after a short delay must replace the object in its remembered location. The object will appear in correct location and participant must walk over it to collect it. (B) Virtual Arena from a first person perspective. (i) In an experimental trial the object cue will appear on screen, e.g., ball. (ii) Once the object has been located and responded to, the object will appear in the correct location. On control trials (iii) the same object will be cued (i.e., vase) and (iv) the participant is required to walk directly to the visible location. Experimental trials contain an intramaze landmark (traffic cone), the boundary (circular wall), and orientation cues (mountains), control trials have no boundaries or landmark and object remains visible throughout trial.
Figure 2Regions of interest superimposed on MNI single subject template brain; pink = caudate, green = hippocampus, red = parahippocampal gyrus.
Demographic data (mean ± SD) for ketamine users and controls.
| Ketamine users | Poly-drug controls | |
|---|---|---|
| No. of subjects | 11 | 15 |
| Age | 28 ± 4.03 | 26.13 ± 5.25 |
| Gender (male/female) | 8/3 | 10/5 |
| Years in education | 13.80 + /3.29 | 16.47 ± 3.96 |
| Spot-the-word | 47.4 ± 7.09 | 46.93 ± 5.85 |
| Personal history of mental illness | 1/11 | 1/15 |
| Family history of drugs | 2/11 | 1/15 |
| Family history of mental illness | 4/11 | 3/15 |
| Family history of alcoholism | 2/11 | 1/15 |
Group means and SD for subjective report of drug use habits.
| Ketamine users | Poly-drug controls | ||
|---|---|---|---|
| Cannabis | No. of regular users | 8/11 | 4/15 |
| Amount used (time to smoke 1/8 oz) | 2.56 ± 2.19 | 15.00 ± 12.66 | |
| Frequency (days/month) | 21.00 ± 12.25 | 15.5 ± 12.77 | |
| Last used (days) | 3.00 ± 4.87 | 4.50 ± 6.35 | |
| Years of use | 13.88 ± 3.44 | 8.00 ± 2.45 | |
| Ecstasy | No. of regular users | 2/11 | 0/15 |
| Amount used (mg/session) | 277.78 ± 253.86 | ||
| Frequency (days/month) | 1.18 ± 1.49 | ||
| Last used (days) | 219.75 ± 305.79 | ||
| Years of use | 10.22 ± 6.28 | ||
| Cocaine | No. of regular users | 4/11 | 1/15 |
| Amount used (g/session) | 2.13 ± 1.44 | 1.44 | |
| Frequency (days//month) | 6.50 ± 3.70 | 2.00 | |
| Last used (days) | 6.75 ± 9.54 | 3.00 | |
| Years of use | 8.75 ± 1.26 | 7.00 | |
| Alcohol | No. of regular users | 9/11 | 15/15 |
| Amount used (units/session) | 6.89 ± 5.56 | 5.00 ± 3.38 | |
| Frequency (days//month) | 15.33 ± 9.95 | 7.00 ± 5.45 | |
| Last used (days) | 2.22 ± 2.99 | 3.60 ± 3.64 | |
| Years of use | 15.56 ± 3.43 | 10.80 ± 6.60 | |
| Tobacco | No. of regular users | 10/10 | 13/15 |
| Amount used (cigarettes/session) | 10.30 ± 5.90 | 3.31 ± 5.51 | |
| Frequency (days//month) | 24.3 ± 10.94 | 11.31 ± 14.06 | |
| Last used (days) | 0.60 ± 0.70 | 1.5 ± 4.37 | |
| Years of use | 12.90 ± 6.24 | 4.92 ± 8.40 | |
*.
Figure 4Parameter estimates across (A) the right hippocampus (B) left parahippocampal gyrus in ketamine users and controls for navigating from memory compared to walking to a visible object.
Figure 5Parameter estimates of activations in the left caudate for ketamine users and controls between receiving feedback on the correct location of object and collecting the object (memory updating) and walking to a visible object.
Group scores on neurocognitive assessments (Mean ± SD).
| Ketamine users | Poly-drug controls | |
|---|---|---|
| Trail making A | 33.80 ± 10.48* | 24.33 ± 6.59 |
| Trail making B | 46.20 ± 14.53 | 40.07 ± 12.41 |
| Trail making total (B–A) | 12.40 ± 19.81 | 15.73 ± 12.07 |
| Verbal fluency | 7.50 ± 3.21 | 8.53 ± 2.70 |
| Category fluency | 17.70 ± 4.52 | 17.33 ± 3.29 |
| Prose recall immediate | 6.45 ± 2.42 | 7.87 ± 3.43 |
| Prose recall delayed | 5.80 ± 2.16 | 7.50 ± 3.15 |
| N-back (1-back) | ||
| No. correct responses | 38.20 ± 11.30 | 43.62 ± 10.23 |
| No. false alarms | 7.50 ± 6.24 | 3.15 ± 3.96 |
| d prime score | 1.98 ± 1.13* | 3.05 ± 1.19 |
| C score | 0.10 ± 0.22 | 0.10 ± 0.22 |
| N-back (2-back) | ||
| No. correct responses | 27.00 ± 12.74 | 35.62 ± 13.12 |
| No. false alarms | 12.60 ± 6.50 | 7.77 ± 6.26 |
| | 0.93 ± 1.26* | 1.85 ± 1.28 |
| | 0.23 ± 0.28 | 0.13 ± 0.31 |
*.
Group scores on assessments of psychological wellbeing (Mean ± SD).
| Ketamine users | Poly-drug controls | |
|---|---|---|
| SPQ cognitive/perceptual | 9.60 ± 8.54* | 3.00 ± 2.88 |
| SPQ interpersonal | 9.56 ± 8.16* | 4.47 ± 3.23 |
| SPQ disorganization | 9.20 ± 3.91* | 3.07 ± 4.43 |
| BDI | 15.40 ± 9.18* | 6.27 ± 9.16 |
| STAI | 44.60 ± 8.92** | 33.20 ± 6.04 |
| PDI distress | 12.90 ± 12.02* | 3.67 ± 5.52 |
| PDI conviction | 19.50 ± 19.50* | 5.40 ± 8.46 |
| PDI preoccupation | 14.60 ± 19.82 | 4.47 ± 7.21 |
| DES | 27 ± 21.67* | 8.95 ± 7.67 |
| LDQ | 15.25 ± 5.65** | 1.13 ± 3.34 |
*.